Page last updated: 2024-12-10
cx717
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
CX717: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 3323368 |
CHEMBL ID | 4791762 |
SCHEMBL ID | 243542 |
MeSH ID | M0537916 |
Synonyms (23)
Synonym |
---|
OPREA1_513346 |
cx717 |
2,1,3-benzoxadiazol-5-yl(morpholin-4-yl)methanone |
867276-98-0 |
cx 717 |
cx-717 |
cx 717 (pharmaceutical) |
SCHEMBL243542 |
CS-0256234 |
DB05047 |
CHEMBL4791762 |
benzo[c][1,2,5]oxadiazol-5-yl(morpholino)methanone |
BS-47001 |
unii-7i12yta3qm |
211735-82-9 |
morpholine, 4-(2,1,3-benzoxadiazol-5-ylcarbonyl)- |
2,1,3-benzoxadiazol-5-yl-4-morpholinylmethanone |
7I12YTA3QM , |
STARBLD0003244 |
EX-A6414 |
DTXSID301241632 |
Z2228297363 |
AKOS040758937 |
Research Excerpts
Overview
CX717 is a positive allosteric modulator of the AMPA receptor. It has shown efficacy in rodent and primate cognition models.
Excerpt | Reference | Relevance |
---|---|---|
"CX717 is a positive allosteric modulator of the AMPA receptor that has shown efficacy in rodent and primate cognition models." | ( Acute sleep deprivation: the effects of the AMPAKINE compound CX717 on human cognitive performance, alertness and recovery sleep. Arbon, EL; Boyle, J; Dijk, DJ; James, LM; Johnsen, S; Stanley, N; Wright, N, 2012) | 1.34 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (17)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (11.76) | 29.6817 |
2010's | 10 (58.82) | 24.3611 |
2020's | 5 (29.41) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 59.72
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.
| This Compound (59.72) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 2 (11.76%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 15 (88.24%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |